blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3233837

EP3233837 - TETRAHYDROQUINOLINE SULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  11.10.2019
Database last updated on 02.09.2024
FormerThe patent has been granted
Status updated on  02.11.2018
FormerGrant of patent is intended
Status updated on  05.07.2018
FormerRequest for examination was made
Status updated on  22.09.2017
FormerThe international publication has been made
Status updated on  31.03.2017
Most recent event   Tooltip03.07.2020Lapse of the patent in a contracting state
New state(s): CY, HU, MK		published on 05.08.2020  [2020/32]
Applicant(s)For all designated states
Galderma Research & Development
2400 Route des Colles
Les Templiers
06410 Biot / FR
[2017/43]
Inventor(s)01 / MUSICKI, Branislav
15 Rue Verdi
Bâtiment B
06000 Nice / FR
02 / OUVRY, Gilles
35 Avenue Saint Philippe
06410 Biot / FR
03 / THOREAU, Etienne
8 allée Saint-Pons
06460 Saint Vallier de Thiey / FR
04 / BOUIX-PETER, Claire
48 chemin du Cannet
06220 Vallauris / FR
 [2017/43]
Representative(s)Casalonga
Casalonga & Partners
Bayerstraße 71/73
80335 München / DE
[2017/43]
Application number, filing date15817295.718.12.2015
[2017/43]
WO2015EP80690
Priority number, dateFR2014006303519.12.2014         Original published format: FR 1463035
FR2015005634103.07.2015         Original published format: FR 1556341
[2017/43]
Filing languageFR
Procedural languageFR
PublicationType: A1 Application with search report
No.:WO2016097392
Date:23.06.2016
Language:FR
[2016/25]
Type: A1 Application with search report 
No.:EP3233837
Date:25.10.2017
Language:FR
The application published by WIPO in one of the EPO official languages on 23.06.2016 takes the place of the publication of the European patent application.
[2017/43]
Type: B1 Patent specification 
No.:EP3233837
Date:05.12.2018
Language:FR
[2018/49]
Search report(s)International search report - published on:EP23.06.2016
ClassificationIPC:C07D405/06, C07D401/06, C07D409/06, C07D215/36, C07D401/04, C07D413/06, C07D409/04, C07D405/12, C07D405/04, A61K31/4709, A61P17/00
[2017/43]
CPC:
C07D413/06 (EP,CN,KR,RU,US); C07D405/06 (EP,CN,KR,RU,US); C07D233/70 (CN);
A61K31/4184 (KR,RU); A61K31/4439 (KR,RU); A61P17/04 (EP,RU,US);
A61P17/06 (EP,RU,US); A61P17/10 (EP,RU,US); C07D209/34 (EP,CN,US);
C07D215/36 (EP,CN,US); C07D231/54 (CN); C07D231/56 (EP,CN,US);
C07D235/26 (US); C07D241/08 (CN); C07D249/18 (CN);
C07D261/08 (CN); C07D307/79 (EP,CN,US); C07D309/04 (CN);
C07D401/04 (EP,CN,RU,US); C07D401/06 (EP,CN,KR,RU,US); C07D401/14 (EP,US);
C07D403/04 (EP,CN,US); C07D403/06 (EP,CN,RU,US); C07D405/04 (EP,CN,RU,US);
C07D405/12 (EP,CN,US); C07D405/14 (EP,CN,RU,US); C07D407/04 (EP,CN,US);
C07D409/04 (EP,CN,US); C07D409/06 (EP,CN,RU,US); C07D417/06 (EP,CN,US);
C07D471/10 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/43]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:TETRAHYDROCHINOLINSULFONAMIDDERIVATE ALS INVERSE AGONISTEN VON RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T))[2017/43]
English:TETRAHYDROQUINOLINE SULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T))[2017/43]
French:DÉRIVÉS TÉTRAHYDROQUINOLINES SULFONAMIDES EN TANT QU'AGONISTES INVERSES DU RÉCEPTEUR GAMMA ORPHELIN ASSOCIÉ AUX RÉTINOÏDES ROR GAMMA (T)[2017/43]
Entry into regional phase12.07.2017National basic fee paid 
12.07.2017Designation fee(s) paid 
12.07.2017Examination fee paid 
Examination procedure12.07.2017Examination requested  [2017/43]
12.07.2017Date on which the examining division has become responsible
06.07.2018Communication of intention to grant the patent
17.10.2018Fee for grant paid
17.10.2018Fee for publishing/printing paid
17.10.2018Receipt of the translation of the claim(s)
Opposition(s)06.09.2019No opposition filed within time limit [2019/46]
Fees paidRenewal fee
12.12.2017Renewal fee patent year 03
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU18.12.2015
AL05.12.2018
AT05.12.2018
CY05.12.2018
CZ05.12.2018
DK05.12.2018
EE05.12.2018
ES05.12.2018
FI05.12.2018
HR05.12.2018
IT05.12.2018
LT05.12.2018
LV05.12.2018
MC05.12.2018
MK05.12.2018
MT05.12.2018
NL05.12.2018
PL05.12.2018
RO05.12.2018
RS05.12.2018
SE05.12.2018
SI05.12.2018
SK05.12.2018
SM05.12.2018
TR05.12.2018
IE18.12.2018
LU18.12.2018
BE31.12.2018
CH31.12.2018
LI31.12.2018
BG05.03.2019
NO05.03.2019
GR06.03.2019
IS05.04.2019
PT05.04.2019
[2020/31]
Former [2020/17]AL05.12.2018
AT05.12.2018
CZ05.12.2018
DK05.12.2018
EE05.12.2018
ES05.12.2018
FI05.12.2018
HR05.12.2018
IT05.12.2018
LT05.12.2018
LV05.12.2018
MC05.12.2018
MT05.12.2018
NL05.12.2018
PL05.12.2018
RO05.12.2018
RS05.12.2018
SE05.12.2018
SI05.12.2018
SK05.12.2018
SM05.12.2018
TR05.12.2018
IE18.12.2018
LU18.12.2018
BE31.12.2018
CH31.12.2018
LI31.12.2018
BG05.03.2019
NO05.03.2019
GR06.03.2019
IS05.04.2019
PT05.04.2019
Former [2020/08]AL05.12.2018
AT05.12.2018
CZ05.12.2018
DK05.12.2018
EE05.12.2018
ES05.12.2018
FI05.12.2018
HR05.12.2018
IT05.12.2018
LT05.12.2018
LV05.12.2018
MC05.12.2018
MT05.12.2018
NL05.12.2018
PL05.12.2018
RO05.12.2018
RS05.12.2018
SE05.12.2018
SI05.12.2018
SK05.12.2018
SM05.12.2018
IE18.12.2018
LU18.12.2018
BE31.12.2018
CH31.12.2018
LI31.12.2018
BG05.03.2019
NO05.03.2019
GR06.03.2019
IS05.04.2019
PT05.04.2019
Former [2020/04]AL05.12.2018
AT05.12.2018
CZ05.12.2018
DK05.12.2018
EE05.12.2018
ES05.12.2018
FI05.12.2018
HR05.12.2018
IT05.12.2018
LT05.12.2018
LV05.12.2018
MC05.12.2018
NL05.12.2018
PL05.12.2018
RO05.12.2018
RS05.12.2018
SE05.12.2018
SI05.12.2018
SK05.12.2018
SM05.12.2018
IE18.12.2018
LU18.12.2018
BE31.12.2018
CH31.12.2018
LI31.12.2018
BG05.03.2019
NO05.03.2019
GR06.03.2019
IS05.04.2019
PT05.04.2019
Former [2019/50]AL05.12.2018
AT05.12.2018
CZ05.12.2018
DK05.12.2018
EE05.12.2018
ES05.12.2018
FI05.12.2018
HR05.12.2018
IT05.12.2018
LT05.12.2018
LV05.12.2018
MC05.12.2018
NL05.12.2018
PL05.12.2018
RO05.12.2018
RS05.12.2018
SE05.12.2018
SI05.12.2018
SK05.12.2018
SM05.12.2018
IE18.12.2018
LU18.12.2018
BE31.12.2018
BG05.03.2019
NO05.03.2019
GR06.03.2019
IS05.04.2019
PT05.04.2019
Former [2019/48]AL05.12.2018
AT05.12.2018
CZ05.12.2018
DK05.12.2018
EE05.12.2018
ES05.12.2018
FI05.12.2018
HR05.12.2018
IT05.12.2018
LT05.12.2018
LV05.12.2018
MC05.12.2018
NL05.12.2018
PL05.12.2018
RO05.12.2018
RS05.12.2018
SE05.12.2018
SK05.12.2018
SM05.12.2018
IE18.12.2018
LU18.12.2018
BG05.03.2019
NO05.03.2019
GR06.03.2019
IS05.04.2019
PT05.04.2019
Former [2019/45]AL05.12.2018
AT05.12.2018
CZ05.12.2018
EE05.12.2018
ES05.12.2018
FI05.12.2018
HR05.12.2018
IT05.12.2018
LT05.12.2018
LV05.12.2018
MC05.12.2018
NL05.12.2018
PL05.12.2018
RO05.12.2018
RS05.12.2018
SE05.12.2018
SK05.12.2018
SM05.12.2018
LU18.12.2018
BG05.03.2019
NO05.03.2019
GR06.03.2019
IS05.04.2019
PT05.04.2019
Former [2019/39]AL05.12.2018
AT05.12.2018
CZ05.12.2018
EE05.12.2018
ES05.12.2018
FI05.12.2018
HR05.12.2018
IT05.12.2018
LT05.12.2018
LV05.12.2018
NL05.12.2018
PL05.12.2018
RO05.12.2018
RS05.12.2018
SE05.12.2018
SK05.12.2018
SM05.12.2018
LU18.12.2018
BG05.03.2019
NO05.03.2019
GR06.03.2019
IS05.04.2019
PT05.04.2019
Former [2019/37]AL05.12.2018
AT05.12.2018
CZ05.12.2018
EE05.12.2018
ES05.12.2018
FI05.12.2018
HR05.12.2018
IT05.12.2018
LT05.12.2018
LV05.12.2018
NL05.12.2018
PL05.12.2018
RO05.12.2018
RS05.12.2018
SE05.12.2018
SM05.12.2018
BG05.03.2019
NO05.03.2019
GR06.03.2019
PT05.04.2019
Former [2019/35]AL05.12.2018
AT05.12.2018
CZ05.12.2018
ES05.12.2018
FI05.12.2018
HR05.12.2018
IT05.12.2018
LT05.12.2018
LV05.12.2018
NL05.12.2018
PL05.12.2018
RS05.12.2018
SE05.12.2018
BG05.03.2019
NO05.03.2019
GR06.03.2019
PT05.04.2019
Former [2019/34]AL05.12.2018
AT05.12.2018
ES05.12.2018
FI05.12.2018
HR05.12.2018
IT05.12.2018
LT05.12.2018
LV05.12.2018
NL05.12.2018
RS05.12.2018
SE05.12.2018
BG05.03.2019
NO05.03.2019
GR06.03.2019
PT05.04.2019
Former [2019/33]AL05.12.2018
AT05.12.2018
ES05.12.2018
FI05.12.2018
HR05.12.2018
LT05.12.2018
LV05.12.2018
NL05.12.2018
RS05.12.2018
SE05.12.2018
BG05.03.2019
NO05.03.2019
GR06.03.2019
PT05.04.2019
Former [2019/30]AL05.12.2018
AT05.12.2018
ES05.12.2018
FI05.12.2018
HR05.12.2018
LT05.12.2018
LV05.12.2018
NL05.12.2018
RS05.12.2018
SE05.12.2018
BG05.03.2019
NO05.03.2019
GR06.03.2019
Former [2019/26]AL05.12.2018
AT05.12.2018
ES05.12.2018
FI05.12.2018
HR05.12.2018
LT05.12.2018
LV05.12.2018
RS05.12.2018
SE05.12.2018
BG05.03.2019
NO05.03.2019
GR06.03.2019
Former [2019/25]AT05.12.2018
ES05.12.2018
FI05.12.2018
HR05.12.2018
LT05.12.2018
LV05.12.2018
RS05.12.2018
SE05.12.2018
BG05.03.2019
NO05.03.2019
GR06.03.2019
Former [2019/24]AT05.12.2018
ES05.12.2018
FI05.12.2018
HR05.12.2018
LT05.12.2018
LV05.12.2018
SE05.12.2018
BG05.03.2019
NO05.03.2019
GR06.03.2019
Former [2019/23]AT05.12.2018
ES05.12.2018
FI05.12.2018
HR05.12.2018
LT05.12.2018
LV05.12.2018
BG05.03.2019
NO05.03.2019
Former [2019/22]FI05.12.2018
LT05.12.2018
BG05.03.2019
NO05.03.2019
Former [2019/21]FI05.12.2018
LT05.12.2018
NO05.03.2019
Former [2019/20]LT05.12.2018
NO05.03.2019
Cited inInternational search[A]WO2011137089  (US HEALTH [US], et al) [A] 1-16* claims 1, 2, 7, 22; compound 41 *;
 [AD]WO2013160418  (GLAXO GROUP LTD [GB]) [AD] 1-16 * claims 1, 31-34, 37; compounds E6, 102 *;
 [AD]WO2014090712  (HOFFMANN LA ROCHE [CH], et al) [AD] 1-16 * page 1, paragraphs 1-3; examples 2, 6, 11, 16, ...; claims 1, 2, 34, 36 *;
 [A]  - YAN ZHANG ET AL, "Discovery of 2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide derivatives as new ROR[gamma] inhibitors using virtual screening, synthesis and biological evaluation", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, (20140322), vol. 78, doi:10.1016/J.EJMECH.2014.03.065, ISSN 0223-5234, pages 431 - 441, XP028847891 [A] 1-16 * the whole document * * table 3 *

DOI:   http://dx.doi.org/10.1016/j.ejmech.2014.03.065
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.